ACIC Pharmaceuticals

About Us

From Molecule to Market

 

ACIC provides clients and partners with active pharmaceutical ingredients (API’s), finished dosage forms, injectables, contract manufacturing services, process development and optimization, regulatory services, clinical services from cGMP and FDA inspected facilities. ACIC and our clients and partners have established a tremendous reputation and are recognized for high quality products and performance efficacy.

 

Automatic Inspection Equipment

Key Supplier

ACIC was the API supplier in the first Paragraph IV challenge and continues to be very active in many Paragraph IV and ANDA filings today, ACIC is also active in new molecules and new NDAs.

Regulatory

Over the years, ACIC has assisted pharmaceutical and biotech companies develop new molecules and optimize process’s which lead to our successful approval and launch of a new product in Japan in 2009, and globally in 2014. We have more molecules in advance stages of clinical testing.

Global Team

Our global team of seasoned professional will work with you to establish a mutually beneficial relationship. We will be there from start to finish every step of the way, from Molecule to Market. Our reputation is based on your success.

Our Team

 Luciano Calenti

Luciano Calenti

Founder & CEO – ACIC Pharmaceuticals

Luciano has been involved in pharmaceuticals in Europe since the late sixties and arrived in North America in 1969 to join the pioneers of the generic industry and became a key supplier of antibiotics to both the branded and generic industries.  He moved to Canada in 1972 to build the first API antibiotic plant in Canada, and in 1973, founded ACIC and masterminded the Corporation’s evolution from distribution to research and development, as well as manufacturing in both APIs and Pharmaceuticals for the pharmaceutical industry worldwide. Luciano was one of the founders of Canadian Drug Manufacturers’ Association (CDMA) and served as Chairman for three and a half years from 1985-1988.

 

Chris Rayfield

Chris Rayfield

President – ACIC Pharmaceuticals

Chris Rayfield has been a valued member of the ACIC Pharmaceuticals team for almost 30 years. He has held various positions within the company of increasing responsibility and currently serves as President of the organization overseeing the Sales, Marketing, and Operations of the company. Chris is a past Board member of GPhA (now AAM) which is the Generic Pharmaceutical Association Advocacy Group in the USA and also served 3 terms as a Board of Director and Executive Committee Member of DCAT (Drug Chemical and Associated Technology) which is a business development and Trade Organization based on the USA. Chris received his Diploma in Business Administration, Marketing from Sheridan College then went on to receive a Degree of Bachelor of Administration, General Management in 1995 from Lakehead University.

Bart

Bart Grochowski

Vice President, Sales – USA

Bart Grochowski is the Vice President of Sales at ACIC Pharmaceuticals, Inc. Bart brings a wealth of experience in the pharmaceutical industry with over 20 years in business development and commercial sales roles in the United States and in Europe. Bart has a multidisciplinary background in Biochemistry, Molecular Biology, Biotechnology, and Informatics. He holds a Bachelor of Science degree in Biochemistry from Stevens Institute of Technology in Hoboken, NJ and earned his M.S. in Bioinformatics at the University of Sciences in Philadelphia. Bart has completed a Lean Six Sigma certification and has a vast knowledge of science and applied statistics. Bart has lived in United States and Europe throughout his career.

William

William Nightingale

Vice President, Business Development

William Nightingale is the Vice President of Business Development at ACIC Pharmaceuticals, Inc. with over 30 years experience working with API and finished dosage form manufacturers, as well as service providers, within the pharmaceutical industry.   William brings a vast knowledge and experience, with an undergraduate degree from UofT and an MBA from Wilfred Laurier University. 

Bart

Andrew Gall

Chief Financial Officer

Andrew Gall is the Chief Financial Officer of the ACIC group of entities. With over 25 years of experience from senior executive roles, Andrew has a demonstrated and substantial track record of driving both strategy and financial operations. He has successfully and routinely turned around underperforming organizations, rolled out highly successful new products and services, and driven mergers, operational transformations, and well-received change management initiatives. Andrew has more than 2 decades of experience in mergers, change management, general management, finance, business development, strategy, risk management, legal, governance, information technology, and human resources. In addition to holding an Executive MBA from University of Toronto and an Honours BBA from Wilfrid Laurier University, Andrew is a Fellow Chartered Professional Accountant (FCPA, FCMA), Chartered Director (C. Dir.).

Sarah H

Sarah Hoogmoed

Vice President- Scientific Affairs

Sarah Hoogmoed brings over 11 years of dedicated service and expertise to her role as Vice President of Scientific Affairs at ACIC Pharmaceuticals Inc. Sarah’s journey in the pharmaceutical sector began with a strong academic foundation in pharmaceutical sciences, culminating in a Master’s degree in Regulatory Affairs and Quality Assurance from Temple University. This educational background, coupled with her hands-on experience, has equipped her with a comprehensive understanding of regulatory frameworks and quality standards critical to the industry. Under Sarah’s stewardship, the Scientific Affairs division has thrived, achieving milestones in product development and regulatory compliance. Sarah holds a deep-seated belief in the power of science to transform lives and remains committed to upholding the highest standards of integrity and ethical conduct in all scientific endeavors. 

Our History

1973

ACIC Founded

  • In the mid 1970’s, ACIC was responsible for the first antibiotic manufacturing site in Canada. What started as a fine chemical company manufacturing, suppling and sourcing API’s has grown to include a global network of FDA inspected and cGMP compliant partner manufacturing plants. Manufacturing, developing and providing API’s and licensing products to the North American market. To assist clients and customers along each stage of the process ACIC expanded on their services to meet the ever changing and expanding demand of our clients.
1976

ACIC formed as a Marketing and Distribution Organization

  • Our initial product offering included Allopurinol, Amitriptyline, and Erythromycin. A successful track record of manufacturers allowed product pipeline to grow quickly.
1986

ACIC opens its first R&D Lab for Chemical Synthesis

  • Over the years, ACIC has developed international experience in the following areas: Analytical Method Development and Validation, Process Optimization, Synthesis & Fermentation, Regulatory Support, Clinical / Pilot / Validation Production under cGMP, Industrial Production
1987

ACIC builds Synthesis Plant in Brantford, Canada

  • The facility housed a complement of 1000 L stainless steel and glass-lined reactors. Approved by the US FDA and the Canadian TPD, the focus was on small volume / high value products and filled a niche in novel process development.
1991

ACIC becomes leading manufacturer of AZT API

  • Amid a growing controversy over access to badly needed medicines for AIDS patients, ACIC develops a novel process for the production of AZT API. ACIC supplies material to partners in over 30 countries and receives its process patent shortly thereafter.
1993

ACIC / SIGNA Joint Venture Agreement

  • Signa, an established API manufacturer in Mexico, was ideally positioned to take advantage of NAFTA. At the time, Signa was a 20,000 square meter facility with over 300,000 liters of manufacturing capacity. Over the years, Signa has grown to be a world-class API facility
1993

ACIC / CANLAC Joint Venture Agreement

  • CANLAC was a state-of-the-art 14 million dollar facility producing 10,000 metric tons of Lactulose per year. The facility was strategically linked to its source of key starting material. ACIC assumed technical, regulatory and marketing responsibilities for the JV.
1993

ACIC Opens European Sales Office

  • The international marketing of Lactulose from CANLAC was handled by ACIC EuropeACIC EU successfully partnered with European pharmaceutical companies to commercialize CANLAC’s product. Since 1993, ACIC EU has been actively developing specialty products for API markets in Europe and other countries.
1994

ACIC builds new R&D Facilities

  • A 20,000 square foot facility housed new R&D Labs and analytical equipment. Investment enabled ACIC to attract highly qualified researchers to the company. ACIC became a reputable player in custom / contract research and synthesis.
1995

ACIC Expands Manufacturing Unit

  • ACIC exported products to the US and 40 other countries. ACIC filed 30 DMFs from its own facilities. By 1995, ACIC had a significant number of process patents including patents for AZT, Nadolol, and Fluconazole.
1996

Start of Specialty Pharma Group

  • Founded Methapharm, ACIC’s Specialty branded affiliate through in-licensing Provocholine® (methacholine chloride) from a global branded company. Product approved and launched globally.
2004

New Head Office Opens

  • ACIC’s newest facility houses our Regulatory Services Group, cGMP compliance teams, and Alliance Management group. The Specialty Pharma Group operates from the same location as well as from a US distribution centre in Florida.
2006

ACIC MACHINERY

    • ACIC Machinery Division was established to meet our clients machinery requirements. We offer injectable manufacturing for high potency and nuclear injectable products as well as state of the art inspection machines with artificial intelligence.